

November 10, 2020

**BSE Limited**

The Corporate Relationship Department  
P.J. Towers,  
Dalal Street,  
Mumbai - 400001

**Scrip Code: 540788**

Dear Sir/ Madam,

**Sub: Outcome of meeting of the Board of Directors held on November 10, 2020, pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

This is to inform you that the Board of Directors of the Company, at their meeting held today at 3 p.m. has, inter alia, considered and approved the un-audited financial results of the Company for the quarter ended September 30, 2020.

A copy of Unaudited Financial Results and Limited Review Report as received from Statutory Auditors is enclosed for your information and record.


The meeting of the Board of Directors concluded at 5 p.m.

We request you to disseminate the above information on your website.

Thanking you.

Yours Faithfully,

For Aspira Pathlab & Diagnostics Limited

  
**Mamta Mav**  
Company Secretary  
Encl : As above



**Aspira Pathlab & Diagnostics Limited**

(CIN L85100MH1973PLC289209)

Reg. Office : Flat No. 2, R.D. Shah Bldg., Shradhdhanand Road, Opp. Railway Station, Ghatkopar (W), Mumbai -400086  
Unaudited Financial Results for the Quarter and Six months ended 30th September, 2020

(Rs. in Lakhs)

Particulars	Quarter ended			Six Months		Year ended
	30-Sep-20 (Unaudited)	30-Jun-20 (Unaudited)	30-Sep-19 (Unaudited)	30-Sep-20 (Unaudited)	30-Sep-19 (Unaudited)	31-Mar-20 (Audited)
<b>1. Income</b>						
(a) Revenue from Operations						
Sales/Income from Operations	537.56	152.23	232.54	689.79	422.86	841.64
Other Operating Income						-
(b) Other Income	6.73	6.84	7.43	13.57	14.76	28.80
<b>Total income</b>	<b>544.29</b>	<b>159.07</b>	<b>239.96</b>	<b>703.35</b>	<b>437.61</b>	<b>870.44</b>
<b>2. Expenses</b>						
(a) Cost of Materials consumed	103.09	28.28	44.63	131.37	97.25	198.76
(b) Purchase of stock-in-trade		-			-	-
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade		-			-	-
(d) Employee benefits expense	95.34	85.55	120.21	180.89	231.29	494.77
(e) Finance Costs	24.58	23.71	24.08	48.29	48.87	101.16
(f) Depreciation and amortisation expense	35.44	36.41	40.63	71.85	80.85	166.04
(g) Other expenses	152.93	48.11	96.44	201.05	170.11	333.76
<b>Total Expenses</b>	<b>411.39</b>	<b>222.05</b>	<b>325.99</b>	<b>633.44</b>	<b>628.38</b>	<b>1,294.50</b>
<b>3. Profit / (Loss) before exceptional items and tax (1-2)</b>	<b>132.90</b>	<b>(62.99)</b>	<b>(86.02)</b>	<b>69.91</b>	<b>(190.76)</b>	<b>(424.06)</b>
4. Exceptional Items	-	-	-	-	-	-
<b>5. Profit / (Loss) before tax (3+4)</b>	<b>132.90</b>	<b>(62.99)</b>	<b>(86.02)</b>	<b>69.91</b>	<b>(190.76)</b>	<b>(424.06)</b>
6. Tax Expenses	-	-	-	-	-	-
<b>7. Profit / (Loss) after tax (5-6)</b>	<b>132.90</b>	<b>(62.99)</b>	<b>(86.02)</b>	<b>69.91</b>	<b>(190.76)</b>	<b>(424.06)</b>
8. Other Comprehensive income (net of tax)	-	-	-	-	-	(1.00)
<b>9. Total Comprehensive income (7+8)</b>	<b>132.90</b>	<b>(62.99)</b>	<b>(86.02)</b>	<b>69.91</b>	<b>(190.76)</b>	<b>(425.06)</b>
10. Paid up Equity share capital ( face value of Rs.10 each)	929.30	929.30	819.30	929.30	819.30	929.30
11. Other Equity						(549.21)
<b>12. Earning per share</b>						
(a) Basic	1.43	(0.68)	(1.05)	0.75	(2.33)	(4.56)
(b) Diluted	1.43	(0.68)	(1.05)	0.75	(2.33)	(4.95)

**Notes**

- The above unaudited financial results of the Company for the quarter and six months ended September 30, 2020 have been reviewed and recommended by the Audit Committee and thereafter approved by the Board of Directors at its meeting held on 10th November, 2020.
- The above unaudited financial results for the quarter and six month ended 30th September 2020 has been subjected to limited review by statutory auditors of the Company. The auditors have expressed an unmodified opinion in the limited review report for the quarter and six months ended 30th September 2020. Also the figures for the quarter and six months ended 30th September 2019 were only reviewed and not subjected to audit.
- These unaudited financial results of the Company have been prepared in accordance with Indian Accounting standards (Ind AS) prescribed under Section 133 of the Companies Act 2013 read with Companies (Indian Accounting Standard) Rules, 2015, and other recognised accounting principles generally accepted in India.
- The Company has taken into account the possible impacts of COVID-19 in preparation of the interim financial results. The Company is continuously monitoring the situation and taking appropriate action, as necessary to scale up operations, in due compliance with the applicable regulations. The Company expects to recover the carrying amount of all its assets including inventories, receivables, investments and other financial and non-financial assets in the ordinary course of business based on the internal and external information available up to the date of approval of these financial results.
- The previous period figures have been regrouped/rearrange/reclassified wherever necessary.

FOR ASPIRA PATHLAB & DIAGNOSTICS LIMITED

Dr. Pankaj J. Shah  
Managing Director  
Din No. 02836324

Place : Mumbai  
Date : 10.11.2020



**ASPIRA PATHLAB & DIAGNOSTICS LIMITED**

CIN : L85100MH1973PLC289209

Flat No. 2, R D Shah Bldg, Shradadhanand Road

Opp: Rly St. Ghatkopar (W), Mumbai -400086

Tel No: 022-71975756 Mail ID : support@aspiradiagnostics.com

Website : www.aspiradiagnostics.com

Statement of Assets and Liabilities

(Rs. in Lakhs)

Particulars	As at 30th September 2020 (un-audited)	As at 31st March 2020 (Audited)
<b>A ASSETS</b>		
<b>Non-current assets</b>		
Property, plant and equipment	457.69	503.05
Right of Use Assets	77.81	100.56
Goodwill	265.18	265.18
Other Intangible assets	16.24	0.78
Financial Assests		
(i) Loans	9.15	10.13
(ii) Others	225.00	225.00
Deferred tax assets (net)	0.00	0.00
Other Non-current financial assests	0.00	0.00
<b>Total non-current assets</b>	<b>1,051.08</b>	<b>1,104.70</b>
<b>Current Assets</b>		
Inventories	44.81	27.65
Financial Assests		
(i) Trade Receivables	168.79	60.46
(ii) Cash and Cash Equivalents	24.99	9.65
(iii) Bank balances other than (ii) above	100.00	100.00
(iv) Others financial assets	120.70	107.20
Other Current Assets	26.08	23.86
<b>Total Current Assets</b>	<b>485.37</b>	<b>328.83</b>
<b>Total Assets</b>	<b>1,536.45</b>	<b>1,433.53</b>
<b>B EQUITY AND LIABILITIES</b>		
<b>EQUITY</b>		
Equity share Capital	929.30	929.30
Other equity	(479.30)	(549.21)
<b>Total Equity</b>	<b>450.00</b>	<b>380.09</b>
<b>LIABILITIES</b>		
<b>Non-current liabilities</b>		
<b>Financial liabilities</b>		
(i) Borrowings	664.43	455.16
(ii) Lease liabilities	49.96	64.19
(iii) Other Financial liabilities	0.00	0.00
Provisions	26.68	21.95
<b>Total non-current liabilities</b>	<b>741.07</b>	<b>541.30</b>
<b>Current liabilities</b>		
<b>Financial liabilities</b>		
(i) Borrowings	97.16	231.83
(ii) Lease liabilities	39.67	48.59
(iii) Trade paybles	32.26	40.10
(iv) Other financial liabilities	50.86	51.59
Other current liabilities	125.37	139.97
Provisions	0.07	0.06
Current tax liabilities (Net)	-	-
<b>Total current liabilities</b>	<b>345.38</b>	<b>512.14</b>
<b>Total Liabilities</b>	<b>1,086.45</b>	<b>1,053.44</b>
<b>Total Equity and Liabilities</b>	<b>1,536.45</b>	<b>1,433.53</b>

FOR ASPIRA PATHLAB & DIAGNOSTICS LIMITED

Dr. Pankaj J. Shah  
Managing Director

DIN: 02836324  
Place : Mumbai  
Date : 10.11.2020



Aspira Pathlab & Diagnostics Limited

(CIN L85100MH1973PLC289209)

Reg. Office : Flat No. 2, R.D. Shah Bldg., Shradhanand Road, Opp. Railway Station, Ghatkopar (W), Mumbai -400086

Cash flow Statement for the half year ended 30th September 2020

(Rs. In Lakhs)

Particulars	For the year ended	For the year ended
	30.09.2020 (₹)	30.09.2019 (₹)
	( Un-Audited)	( Un-Audited)
<b>A CASH FLOW FROM OPERATING ACTIVITIES</b>		
Profit/(Loss) for the year	69.91	(190.76)
Adjustments for:		
Interest income	(13.57)	(14.76)
Finance Costs	48.29	48.87
Depreciation and amortisation expenses	71.85	63.46
Provision for doubtful debts	1.96	-
<b>CASH GENERATED BEFORE WORKING CAPITAL CHANGES</b>	<b>178.44</b>	<b>(93.18)</b>
Adjustments for:		
(Increase)/Decrease in Trade receivables	(110.29)	14.39
(Increase)/Decrease in Inventories	(17.16)	1.99
(Increase)/Decrease in Current Security deposits and others	(13.50)	(17.33)
(Increase)/Decrease in other Non Current advances	0.98	(0.06)
(Increase)/Decrease in Short term advances	(2.22)	(4.08)
Increase/(Decrease) in Trade payables	(7.84)	(15.62)
Increase/(Decrease) in other Current Provisions	0.01	0.02
Increase/(Decrease) in other Non Current Provisions	4.72	3.38
Increase/(Decrease) in other Current Liabilities	(14.60)	6.50
Increase/(Decrease) in Other financial liabilities	(0.73)	2.99
Increase/(Decrease) in Other Non-Current liabilities	-	(50.00)
<b>CASH GENERATED FROM OPERATIONS</b>	<b>17.81</b>	<b>(151.01)</b>
Taxes Paid ( net of refunds)	-	-
<b>NET CASH (USED IN)/ GENERATED FROM OPERATING ACTIVITIES(A)</b>	<b>17.81</b>	<b>(151.01)</b>
<b>B CASH FLOW FROM INVESTING ACTIVITIES</b>		
Purchase of property , plant and equipment	(2.68)	(0.83)
Purchase of Intangible assets	(16.52)	-
Interest Received	13.57	14.76
<b>NET CASH FLOW (USED IN)/ GENERATED FROM INVESTING ACTIVITIES - (B)</b>	<b>(5.63)</b>	<b>13.92</b>
<b>C CASH FLOW FROM FINANCING ACTIVITIES</b>		
Proceeds from Long term borrowings	209.27	202.03
Repayment of long term borrowings	-	(4.87)
Repayment of Lease Liability	(23.15)	-
Interest paid	(48.29)	(48.87)
<b>NET CASH (USED IN)/ GENERATED FROM FINANCING ACTIVITIES (C)</b>	<b>137.83</b>	<b>148.29</b>
Net Increase/(Decrease) in Cash and Cash Equivalents (A+B+C)	150.00	11.20
Add:Cash and Cash Equivalents at the beginning of the year	9.65	9.64
Less: Cash Credits at the beginning of the year	(231.83)	(196.49)
Adjusted cash & cash equivalents at the beginning of the year	(222.17)	(186.85)
<b>Cash and Cash Equivalents at the end of the year</b>	<b>(72.17)</b>	<b>(175.65)</b>
<b>Components of cash and cash equivalents comprise:</b>		
Cash in hand	23.80	11.50
Balances with banks:		
-In Current Accounts	0.84	0.70
-In Escrow Account	0.35	0.26
-In Cash Credit Accounts	(97.16)	(188.11)
Cash and Cash Equivalents in cash flow statement	(72.17)	(175.65)



Significant Accounting Policies & Notes

The Significant accounting policies and notes to accounts referred to above form an integral part of the

**Note:**

- 1) Cash and Cash equivalents represents cash in hand and balances with banks and Overdraft Facilities.
- 2) The above Cash Flow Statement has been prepared under the 'Indirect Method' as set out in the Accounting Standard (Ind AS) 7
- 3) Previous year figures have been regrouped and reclassified where necessary to conform to current year's classification.

**FOR ASPIRA PATHLAB & DIAGNOSTICS LIMITED**



**Dr. Pankaj J. Shah**  
**Managing Director**

DIN. 02836324  
Place : Mumbai  
Date : 10.11.2020





**Independent Auditor's Limited Review Report on Unaudited Quarterly and year to date Financial Results of Aspira Pathlab & Diagnostics Limited under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements ) Regulations, 2015, as amended**

To  
**The Board of Directors**  
**Aspira Pathlab & Diagnostics Limited**

We have reviewed the accompanying statement of **Unaudited Financial Results of Aspira Pathlab & Diagnostics Limited** (“the Company”) for the quarter and six months ended September 30, 2020 (“the Statement”) attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“the SEBI LODR Regulation”) including relevant circulars issued by the SEBI from time to time.

The Statement, which is the responsibility of the Company's Management and approved by the Board of Directors of the Company, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “Interim Financial Reporting” (“Ind AS 34”), prescribed under section 133 of the Companies Act, 2013 (“the Act”) read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, “*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*” issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the accounting principles laid down in Ind AS 34 prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI LODR Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **P Khetan & Co**  
Chartered Accountant  
Firm Reg. No- 327386E

Rajesh Sarfare  
Partner

Membership No.- 140399

UDIN: 20140399AAAAAM8059



Place- Mumbai  
Date- 10.11.2020